Tracer library / [225Ac]Ac-DOTATATE
[225Ac]Ac-DOTATATE
Also written as DOTATATE; [Ac-225]Ac-DOTATATE; DOTA-TATE; dotatate
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 4
What it is
- Compound class
- DOTA-conjugated somatostatin analog peptide (DOTA-TATE)
- Target / mechanism
- Somatostatin receptor 2 (SSTR2)-targeted alpha-particle therapy PMID 33772332
- Clinical application
- Targeted alpha-particle therapy for SSTR2-expressing neuroendocrine tumors, including GEP-NETs progressing after 177Lu-labeled SSA therapy PMID 42242867
- Theranostic pair
- [68Ga]Ga-DOTATATE
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Modular-Lab EAZY Eckert & Ziegler | vendor cassette | SPE | 80-90% | >95% | DOTA-TATE ROTOP, Dresden-Rossendorf, Germany | 34358076 2021 Pharmaceuticals (Basel) the Modular-Lab EAZY (ML EAZY), Eckert & Ziegler - final radiochemical yields of 80–90% for the 225Ac-labeled peptides |
| — | custom manifold | none | 98% | 99.8% | DOTA-(Tyr3)-octreotate (DOTA-TATE) Bachem, Bubendorf, Switzerland | 33772332 2021 Eur J Nucl Med Mol Imaging |
| Modular-Lab EAZY Eckert & Ziegler | vendor cassette | SPE | 80-90% | >95% | DOTA-TATE ROTOP, Dresden-Rossendorf, Germany | 34358076 2021 Pharmaceuticals (Basel) The Modular-Lab EAZY module (GTL) with software Modular-Lab v6.2 was obtained from Eckert & Ziegler (Berlin, Germany). - final radiochemical yields of 80–90% for the 225Ac-labeled peptides |
| Manual synthesis n/a | — | SPE | — | — | DOTATATE | 34053430 2022 Curr Radiopharm PSMA-617, DOTATATE were radiolabelled with 225Actinium in 0.1 M HCl in the presence of ascorbate buffer solution and passed through the C-18 light cartridge for purification |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Preliminary Evaluation of 225 Ac/ 177 Lu-DOTATATE PRRT in Progressive Meningiomas : Efficacy, Dosimetry, and Imaging Insights.2026 · Clin Nucl Med · Prospective
- Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer.2024 · Radiology · Prospective · Phase II
- Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression.2024 · Clin Nucl Med · Prospective
- Targeted Alpha Therapy With [ 225 Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT With [ 177 Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [ 177 Lu]Lu-DOTATATE Treatment : An Observational Study Comparing the Therapeutic Response, Survival, and Clinical Toxicity.2026 · Clin Nucl Med · Retrospective
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Bachem, Bubendorf, ROTOP
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTATATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 15 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64, Ga-68. Stage set/updated at stage 23 from PMID 42242867: 'Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.'. | Stage 30 (2026-09-18): Stage was 'Phase 1b/3 clinical trial'; normalised to 'Clinical research', original wording kept here.